Patents by Inventor Nanqiao Zheng

Nanqiao Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230125046
    Abstract: A cyano-substituted pyridine and cyano-substituted pyrimidine compound and a preparation method therefor and an application thereof, which specifically relate to a compound represented by formula (I) and an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, and a prodrug thereof, and a preparation method therefor and an application thereof in the preparation of a drug as a kinase inhibitor. The compound has good inhibitory activity against kinases such as FGFR4 and mutant FGFR4V550L.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 20, 2023
    Inventors: Qiang Zhang, Leifu Yang, Nanqiao Zheng, Shannan Yu, Yueming Sun, Zhenke Guo
  • Patent number: 11548900
    Abstract: Provided are an oxazino-quinazoline and oxazino-quinoline type compound, a preparation method, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method, and uses thereof in preparing a drug acting as a kinase inhibitor.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: January 10, 2023
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Nanqiao Zheng, Hailong Yang, Leifu Yang, Hongbo Zhang, Likai Zhou, Zhanqiang Xu
  • Patent number: 11479559
    Abstract: The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: October 25, 2022
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yansheng Liu, Xingfu Li, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • Patent number: 11407760
    Abstract: The present invention relates to a dioxinoquinoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2 and c-MET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 9, 2022
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yueming Sun, Yansheng Liu, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • Publication number: 20220002308
    Abstract: Disclosed are a class of compounds as inhibitors of kinases such as TRK, c-MET, AXL, MER and/or VEGFR2, compositions and use thereof. In particular, disclosed are a class of compounds (as shown in formula (1)) or isomers, solvates, hydrates, pharmaceutically acceptable salts, and prodrugs thereof having strong inhibition activities for kinases such as TRK, c-MET, AXL, MER and/or VEGFR2, and pharmaceutical compositions comprising said compounds. Also disclosed is use of the compounds or pharmaceutical compositions in the preparation of a medicament for treating autoimmune diseases or cancers.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 6, 2022
    Inventors: Qiang Zhang, Shannan Yu, Yueming Sun, Leifu Yang, Nanqiao Zheng
  • Patent number: 10980809
    Abstract: The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.
    Type: Grant
    Filed: February 11, 2018
    Date of Patent: April 20, 2021
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Shannan Yu, Zhongxiang Wang, Shouye Feng, Zhanqiang Xu
  • Publication number: 20210040114
    Abstract: Provided are an oxazino-quinazoline and oxazino-quinoline type compound, a preparation method, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method, and uses thereof in preparing a drug acting as a kinase inhibitor.
    Type: Application
    Filed: March 5, 2019
    Publication date: February 11, 2021
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Nanqiao Zheng, Hailong Yang, Leifu Yang, Hongbo Zhang, Likai Zhou, Zhanqiang Xu
  • Publication number: 20200399285
    Abstract: The present invention relates to a dioxinoquinoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2 and c-MET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Application
    Filed: January 25, 2019
    Publication date: December 24, 2020
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yueming Sun, Yansheng Liu, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • Publication number: 20200399284
    Abstract: The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Application
    Filed: January 25, 2019
    Publication date: December 24, 2020
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yansheng Liu, Xingfu Li, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • Publication number: 20200061065
    Abstract: The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.
    Type: Application
    Filed: February 11, 2018
    Publication date: February 27, 2020
    Inventors: Qiang Zhang, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Shannan Yu, Zhongxiang Wang, Shouye Feng, Zhanqiang Xu